ABSTRACT
Introduction
Incidentally identified adrenal masses noted by non-invasive imaging or by autopsy are found in 0.5% -10% of the population [1] [2] [3] . The dilemma therefore, is in the setting of an established or questionable extra-adrenal malignancy to differentiate between a benign adrenal mass or metastatic deposit. Characterization of altered adrenal morphology is clearly important for disease management and prognosis. Current non-invasive imaging modalities include computed tomography (CT), magnetic resonance imaging (MRI), F-18 fluorodeoxyglucose positron emission tomography (F-18 FDG PET) and more recently integrated PET-CT.
Unenhanced CT and MRI images have been used to distinguish lipid containing adrenal adenomas from metastases and other lesions on the basis of the presence of fat [4] . An unenhanced CT attenuation threshold of ≤10 Hounsfield Units (HU) is used as a discriminating index to diagnose a lipid rich adrenal adenoma [3, [5] [6] [7] . Outof-phase MRI imaging shows signal dropout due to the presence of intracellular lipid in lipid rich adenomas. Unfortunately, the performance characteristics are relatively poor, as 30% of adenomas are lipid poor, and in addition to malignant pathology, have a higher attenua-tion (HU) value [8, 9] . Lesion size and shape may be helpful in differentiating a benign from a malignant adrenal mass, but again they are not specific [10] .
The limited accuracy of lesion localization using PET alone, due to the lack of precise anatomical landmarks led to the development of integrated PET-CT to provide anatomic-metabolic information which is considered to be more sensitive and specific than PET alone, when depicting adrenal gland metastasis [11] . However, false positive interpretation even with PET-CT can occur as studies rarely have complete cytological or histological correlation for concordance purposes [11] [12] [13] . Such examples include; 5% of adrenal adenomas, adrenal endothelial cysts, adrenal cortical hyperplasia without chronic inflammatory cell infiltration, phaeochromocytoma and inflammatory or infectious lesions [14] . PET-CT with additional maximum standard uptake value analysis (SUVmax score) is thought to potentially improve the diagnostic accuracy of adrenal lesions in patients with cancer ( Table 1 ) [15] [16] [17] [18] [19] [20] [21] . In spite of this, there is no universally accepted SUV max score to predict malignancy, at any site or a specific score dedicated for the evaluation of the adrenal gland [18] . However, by convention, a common threshold SUV max score > 2.5 is used to distinguish a benign from a malignant process [22] [23] [24] [25] [26] .
The left adrenal gland may be sampled using CT or trans abdominal ultrasound guided fine needle aspiration (FNA), by open or laparoscopic adrenalectomy and more recently endoscopic ultrasound (EUS) guided FNA [10, [27] [28] [29] [30] [31] [32] [33] [34] [35] . EUS FNA is accepted as a highly specific and safe technique for confirming the diagnosis of metastatic disease to the adrenal glands [32] . While lesion size (≥30 mm) and EUS echodensity (hypoechoic) poorly distinguish malignant from benign masses, altered adrenal gland morphology (loss of classic seagull configuration) is highly predictive [10] . EUS FNA of an enlarged left adrenal gland in patients with established or suspected lung cancer was shown to alter the TNM stage and treatment in 70% and 48% of patients, respectively [28] . EUS guided ethanol ablation of left adrenal metastasis from non-small cell lung carcinoma has also been reported [36] .
The aim of the study was to establish the sensitivity and specificity of unenhanced CT attenuation values and to determine the optimal PET-CT SUV max score for predicting left adrenal gland malignancy as compared to a gold standard consisting of EUS FNA cytology with clinical follow-up.
Patients and Methods

Study Design and Setting
A prospectively maintained EUS database was reviewed to identify consecutive patients who underwent left adrenal gland EUS FNA from May 1, 2005 to November 1, 2011. EUS examinations were performed by one of eight experienced endosonographers. Radiologic calculation of unenhanced CT attenuation values and FDG PET-CT SUV max scores were performed by one radiologist who was blinded to any clinical or pathologic data specifically for the purpose of the study. Clinical demographics, radiologic, EUS and cytologic data, in addition to clinical follow up were retrieved and analyzed.
CT Attenuation Analysis of the Left Adrenal Gland
Utilizing transaxial CT slices from an unenhanced CT, a circular or oval manually defined region of interest was placed in the center of the adrenal mass to obtain CT attenuation values in Hounsfield units (HU). A CT slice was selected that allowed at least two thirds of the adrenal mass to be evaluated. An attenuation value of ≥10 HU was considered to represent a non-adenomatous lesion.
Quantitative Analysis of F18-FDG PET Based on Standardized Uptake Values (SUVs)
As per standard technique based on a qualitative visual assessment, PET findings were interpreted as positive if the FDG uptake in an adrenal lesion was greater than or equal to that in the generalized liver and as negative, if lesion uptake was less than that of the liver. A PET-CT SUV max score was calculated by creating an elliptic region of interest over a minimum of two thirds of the adrenal lesion.
Diagnostic Gold Standard-EUS FNA Cytology
An electronic multi-element curved-linear US echoendoscope (GF-UC140P-AL5 or GF-UC 160P-AT8; Olympus) was used to perform FNA with an 8-cm-long, 22-gauge needle (Echotip; Cook Endoscopy, Winston-Salem, NC). Altered adrenal morphology was considered, if the standard seagull configuration was lost to include 1) a general enlargement of the gland akin to a mass; 2) presence of a focal nodule or 3) presence of limb thickening. EUS FNA cytology results were used as the reference standard for final classification of the altered adrenal morphology when determining the presence of benign versus malignant adrenal gland status. Cytology specimens were interpreted as either positive for malignnancy, suspicious for malignancy, atypical, negative for malignancy, or inadequate cellularity for interpretation. For statistical purposes, results that were positive or suspicious for malignancy were considered to be positive and the remaining atypical, negative for malignancy, or inadequate cellularity for interpretation cases were considered to be negative for malignancy.
Statistical Analysis
Continuous variables were reported as mean (SD) or median (interquartile range) and compared by using the Student t test or Mann Whitney U test. Categorical variables were reported as frequency (%) and were compared by either a 2-tailed Fisher exact test or Pearson χ 2 test, when appropriate. An ROC curve analysis was performed to evaluate HU values and SUV max score data to yield the best power distinction for malignant cytology. All tests were 2-sided, with P = 0.05 as the criterion standard for determining significance. The statistical software package JMP Version 9 (SAS Institute Inc., Cary, NC) and MedCalc were used for statistical analysis.
Results
Sixty-two consecutive patients (69 ± 10.5 years) underwent left adrenal EUS FNA to evaluate a mass (n = 31), nodule (n = 17) or limb thickening (n = 14). Prior to the EUS examination, 34 (54.8%) patients had a clinically suspected or established extra-adrenal malignancy including lung (n = 21; 55%)], esophageal (n = 7), gastric (n = 2) and one patient each for gastric gastrointestinal stromal tumor (GIST), pancreas neuroendocrine tumor (NET), breast cancer and colon cancer. Fifty-seven (92%) patients had non-invasive imaging with CT [n = 35, (12/35 performed with IV contrast)] or PET-CT (n = 22) within 4 weeks prior to EUS FNA.
With a median of 3 (IQR 2 -5) FNA passes, in the absence of reported complications, the cytological findings were negative for malignancy (n = 41), positive or suspicious for malignancy (n = 15), atypical (n = 2) or inadequate cellular yield (n = 4). The positive for malignancy cases included metastases from non small cell lung carcinoma (n = 10), esophageal adenocarcinoma (n = 2), pancreas adenocarcinoma (n = 1), breast ductal carcinoma (n = 1) and a GIST (n = 1). Positive cytology was seen more frequently in patients with a personal history or a newly suspected or confirmed cancer diagnosis (13/15 vs 21/47, p = 0.006). (Figures 1 and 2) . The 12 unremarkable CT scans by final report were all performed with IV contrast. The sensitivity and specificity of elevated attenuation values (≥10 HU) by non-enhanced CT alone, by non-enhanced CT as part of integrated PET-CT or a combination of non-enhanced CT cases in addition to the non-enhanced CT component from the PET evaluation are documented in Table 2 & Figure 3 . Using FNA cytology results as the gold standard, ROC curve analysis indicated an optimum cutoff HU value ≥ 25 with an AUC of 0.90 (95% CI, 0.76 -0.98) yielded the best power distinction for malignancy to provide a sensitivity and specificity of 90% and 84.6%, respectively (Figure 4 ).
Evaluation of Unenhanced CT Findings Pre EUS
Quantitative Analysis of PET SUV max
The SUV max for malignant altered morphology was 8.5 ± 3.1, significantly higher (p = 0.0001) than that for benign lesions (3.3 ± 0.7). ROC curve analysis indicated an optimum cutoff SUV max ≥ 4.1 with an AUC of 0.92 (95% CI, 0.72 -0.99) yielding the best power distinction for malignancy, that provided a sensitivity and specificity of 89% and 100%, respectively ( Figure 5) . If that threshold is adopted the false negative rate would correspond to 1/9 (11%). However, if a threshold of ≥2.5 was used instead, as per ROC analysis, then the sensitivity and specificity values correspond to 100% and 23%, respectively.
Unenhanced CT Attenuation plus SUV max Values for Integrated PET-CT
Elevated attenuation values (≥10 HU) accompanied by a SUV max score ≥ 4.1 were noted in 8/9 (88.9%) patients with malignant cytology, revealing a sensitivity and specificity of 89% and 85%, respectively. Elevated attenuation values (≥25 HU) accompanied by a SUV max score ≥ 4.1 were again noted in 8/9 (88.9%) patients with malignant cytology, revealing a sensitivity and specificity of 88.9% and 92.3%, respectively (Figure 6 ).
Unsuspected Altered Adrenal Morphology at EUS
Seventeen of 62 patients had unsuspected altered adrenal morphology at EUS, 4 of whom had evidence of metastatic disease, from either non-small cell lung cancer (n = 2), breast ductal carcinoma (n = 1) or a GIST (n = 1), thus altering management in 4/62 (6.5%) patients.
Clinical Follow Up of Non-Malignant EUS Cytology
Patients were followed clinically for 25 ± 18.5 months, during which period 9/45 (19%) patients died [pancreas adenocarcinoma (n = 7), cholangiocarcinoma (n = 1), non-small cell lung cancer (n = 1)]. The remaining patients with negative left adrenal gland cytology had a diagnosis of non-small cell lung cancer lung (n = 13), esophageal adenocarcinoma (n = 5), pancreas adenocarcinoma (n = 3), and one patient each with gastric, colon, gastric GIST, pancreas NET and rectal adenocarcinoma. Finally, no clinical evidence of extra adrenal malignancy has been noted to date in the remaining 12 patients. 
Discussion
Altered adrenal morphology in patients with extra adrenal malignancy is a clinical conundrum. Approximately, 50% of such patients will have metastatic disease to the adrenal gland, but the remainder will have non-metastatic etiologies including cortical adenomas [36, 37] . Our study observed that an unenhanced CT attenuation value of ≥10 HU for an adrenal lesion is highly sensitive but poorly specific (31% -39%) for malignancy. The high sensitivity is in accordance with adrenalectomy histopathologic findings when correlated with imaging characteristics [38] . In order to improve specificity, recent studies recommend using cut-off values of 20 HU or 25 HU to achieve specificities of 60% or 72%, respecttively [9] . Our ROC analysis using cytology as the gold standard indicates that a cutoff value of 25 HU provides a sensitivity and specificity of 90% and 84.6%, respecttively. In adults, adrenal gland volume and attenuation correlate positively and inversely with age, but the metabolic activity does not alter significantly with age, and therefore PET permits the evaluation of a primary lesion, in addition to metastases as part of non-invasive whole body imaging [39, 40] .
The presented study revealed an optimum cut off PET SUV max of 4.1 (AUC 0.92) as the best power distinction for malignant adrenal lesions (sensitivity 89%; specificity 100%). This value is certainly higher than that re-ported for adrenal metastases elsewhere (SUV max 2.2 -3.4), but the presented study is the only one with complete cytologic correlation rather than an interval imaging evaluation or clinical follow up. The use of a high SUV max threshold may be criticized as it could potentially exclude a considerable number of false-negative results to include hemorrhagic or necrotic metastatic lesions, metastatic lesions < 10 mm as a critical mass of metabolically active malignant cells is required, and metastases from pulmonary bronchoalveolar carcinoma or carcinoid tumors. Hypothetically, if this high SUV max cut off value was the given standard; our false negative rate would correspond to 11%. The ideal threshold SUV max to adopt depends on whether one favors a greater sensitivity and corresponding poor specificity or alteratively a greater specificity with associated poor sensitivity. As for any test, this decision is influenced by the manner in which the test results, whether positive or negative, impact the subsequent diagnostic and therapeutic care.
Two studies evaluating PET for mediastinal lung cancer staging using either mediastinoscopy or mediastinal lymphadenectomy as the diagnostic gold standard determined that the highest diagnostic accuracy was achieved with SUV max values of 4.5 and 5.3 respectively, rather than the traditional value of ≥2.5 [41, 42] . When we applied the conventional value of ≥2.5 to the adrenal gland with direct cytological correlation, the specificity value correspond to a poor and clinically unacceptable 23%.
In order to improve PET-CT diagnostic accuracy, Perri and colleagues combined mean SUV values with a CT histogram analysis revealing a sensitivity and sensitivity of 100% and 97.3%, respectively, leading to a significant reduction in the number of false-positive cases [17] . We evaluated a combination of CT attenuation and SUV max values, noting that an attenuation value of ≥10 HU or ≥25 HU accompanied by a SUV max score ≥ 4.1 revealed a specificity of 89% and 92%, respectively. Although this was a hypothetical evaluation using values much higher than conventional threshold values, it would still suggest that we should perhaps lower our threshold for sampling the adrenal gland, as it could characterize such lesions with greater confidence. Limitations of our study include: referral bias, the small cohort size, a retrospective evaluation of our EUS and cytological data and the absence of the ultimate gold standard, that of histopathology.
In 1996, Chang and colleagues initially described the EUS characterization and FNA of the adrenal gland [43] . The European Society of Gastrointestinal Endoscopy (ESGE) recently released an EUS clinical guideline supporting sampling the adrenal gland [44] . EUS guided sampling has some advantages over image guided percutaneous biopsy. EUS obviates the need for needle traversal through the kidney or lung. Thus, complications such as perinephric hemorrhage, pneumothorax (5% risk) and hemothorax rarely develop. In addition, EUS does not require a saline injection to expand the posterior paravertebral space to facilitate sampling as used by some radiologists [45] . The advantages of EUS must be weighed against the cost differential and considered in the context of local expertise.
In conclusion, accurate characterization of altered adrenal morphology in patients with established or possible malignancy is challenging with the current limitations of standard non-invasive imaging. The conventional threshold values used for CT and PET to distinguish a benign from a malignant adrenal entity for unenhanced CT and that of PET-CT are suboptimal when compared to adrenal gland cytologic evaluation by EUS. Our preliminary study suggests that increasing the HU and SUV max cutoff values used for differentiation would significantly increase specificity. Further prospective studies evaluating higher or variable threshold values may be of benefit, but ultimately sampling of the adrenal gland, confers the best management option for the patient in the setting of malignancy to guide the decision making process.
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